Sugi Predict

Sugi Predict / Targets / TMEM97

TMEM97

Sigma intracellular receptor 2 · Q5BJF2 · TMEM97 on Sugi Atlas →

146,893 patent compounds predicted against TMEM97, 95,884 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL70979 SCHEMBL70979 0.46 9/20
SCHEMBL88169 SCHEMBL88169 0.40 8/20
(+)-Pentazocine (+)-Pentazocine (SCHEMBL2492) 1.00 4/20
Pentazocine Pentazocine (SCHEMBL2493) 1.00 4/20
(+)-Pentazocine (+)-Pentazocine (SCHEMBL40963) 0.98 4/20
Pentazocine Pentazocine (SCHEMBL40964) 0.98 4/20
(+)-Pentazocine (+)-Pentazocine (SCHEMBL42094) 0.83 4/20
SCHEMBL42095 SCHEMBL42095 0.65 4/20
SCHEMBL82397 SCHEMBL82397 0.53 4/20
SCHEMBL92564 SCHEMBL92564 0.52 4/20
SCHEMBL39945 SCHEMBL39945 0.51 4/20
SCHEMBL12450 SCHEMBL12450 0.51 4/20
SCHEMBL62381 SCHEMBL62381 0.51 4/20
SCHEMBL92518 SCHEMBL92518 0.46 4/20
Dextromethorphan Dextromethorphan (SCHEMBL29949) 1.00 3/20
Levomethorphan Levomethorphan (SCHEMBL29950) 1.00 3/20
Nefazodone Nefazodone (SCHEMBL35089) 0.98 3/20
SCHEMBL61848 SCHEMBL61848 0.83 3/20
SCHEMBL61867 SCHEMBL61867 0.74 3/20
SCHEMBL61489 SCHEMBL61489 0.72 3/20

Clinical trials — most relevant to TMEM97 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration PHASE4COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus PHASE2UNKNOWN
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer PHASE2COMPLETED
Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer PHASE1/PHASE2COMPLETED
Novel Clinical Target in Fragile X Syndrome PHASE1WITHDRAWN
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People EARLY_PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Quantification of GADD34 Expression in RA nanCOMPLETED
Brain P-gp and Inflammation in People With Epilepsy nanCOMPLETED
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients nanCOMPLETED
Insulin Detemir in Obesity Management nanACTIVE_NOT_RECRUITING
Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia nanCOMPLETED
Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation nanUNKNOWN
Study of Constitutional Platelet Disease nanUNKNOWN
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Stem Cell Study of Genetics and Drug Addiction nanCOMPLETED
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia nanCOMPLETED
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System nanUNKNOWN
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management nanUNKNOWN
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient nanUNKNOWN
ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial nanUNKNOWN
Coproporphyrine Isomers and Methotrexate Elimination nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Renal Transporters After Renal Transplantation nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TMEM97 binder may also engage these)

ProteinNameSimilarity
Q4R8A8 — 1.000 Q4R8A8 →
Q3MHW7 — 0.997 Q3MHW7 →
Q8VD00 — 0.993 Q8VD00 →
Q6DFQ5 — 0.992 Q6DFQ5 →
Q5U3Y7 — 0.986 Q5U3Y7 →
B0BNG2 — 0.976 B0BNG2 →
Q0V982 — 0.975 Q0V982 →
Q9BZW4 — 0.975 Q9BZW4 →
Q6DCP8 — 0.974 Q6DCP8 →
Q8R1J1 — 0.973 Q8R1J1 →
O48962 — 0.971 O48962 →
Q60457 — 0.970 Q60457 →
P70245 — 0.968 P70245 →
O77761 — 0.967 O77761 →
SOAT1 Sterol O-acyltransferase 1 0.967 landscape →
Q8K2C9 — 0.966 Q8K2C9 →
Q9FTZ2 — 0.966 Q9FTZ2 →
Q9JJ46 — 0.965 Q9JJ46 →
O77760 — 0.965 O77760 →
Q61263 — 0.964 Q61263 →
Q9JJF9 — 0.963 Q9JJF9 →
SOAT2 Sterol O-acyltransferase 2 0.963 landscape →
O42153 — 0.963 O42153 →
Q6ZQE4 — 0.962 Q6ZQE4 →
O70536 — 0.962 O70536 →
A5D6V4 — 0.962 A5D6V4 →
Q8JHF0 — 0.962 Q8JHF0 →
Q3ZBX1 — 0.962 Q3ZBX1 →
Q5U4X7 — 0.962 Q5U4X7 →
Q801G2 — 0.962 Q801G2 →